CONTACT US
Press

egnite Launches CardioCare Research Suite to Accelerate Patient Identification for Leading Cardiovascular Clinical Trials

New Capabilities Automatically Identify Patients for 10 High-Impact 
Structural Heart and Heart Failure Clinical Trials

ALISO VIEJO, Calif. – July 1, 2025 – egnite, Inc., a leading cardiovascular digital health company announced the launch of the CardioCare Research Suite, a significant expansion of its flagship platform designed to streamline and enhance patient identification for clinical trials.

The Research Suite supports ten landmark clinical trials in structural heart and heart failure care, including AIM-HIGHer, ALT-FLOW II, APOLLO, ARTIST, CLASP IIF, CLASP II TR, CORCINCH-HF, EMPOWER, ENCIRCLE, PROGRESS.

This expansion addresses a long-standing challenge in clinical research, ensuring the right patients are surfaced at the right time for trial consideration. Through the use of AI and natural language processing to analyze both structured and unstructured hospital data, the CardioCare Research Suite empowers hospitals to expand access to novel therapies and reduce the operational burden on research teams.

Early adopters of the Research Suite have reported meaningful results:

  • Over 50% of patients identified through the platform had never been seen by the principal investigator or a relevant specialist.
  • 25%–50% of patient consents were sourced directly from CardioCare.
  • Trial coordinators report significantly less time spent identifying candidates.
  • The platform facilitates more precise, patient-focused outreach by trial investigators, addressing the complexity of evolving eligibility criteria.
 

“Since our inception, ambitious programs have expressed a desire to leverage the CardioCare platform to move from passive intake to proactive identification of clinical trial patients,” said Kahla Verhoef, Chief Operating Officer at egnite. “The Research Suite is a direct response to that need, empowering research teams to efficiently surface eligible patients from complex data, align with evolving trial criteria, and engage physicians with precision and confidence.”

egnite’s CardioCare Research Suite is now an available offering to all partner hospitals using the CardioCare platform. With the ability to leverage AI across structured and unstructured data, the platform uniquely equips research teams to accelerate enrollment and drive clinical innovation forward.

__

About egnite, Inc.

egnite is a data-driven digital health company committed to advancing the health of our society through innovative cardiovascular solutions. egnite utilizes AI algorithms and big data to generate business intelligence for healthcare, elevating the role of data in critical decisions. The company, based in Aliso Viejo, California, partners with leading hospitals and life sciences organizations to transform care delivery for cardiovascular patients. For more information, visit www.egnitehealth.com.

# # #

egnite, egnite, Inc., CardioCare and the spark logo are trademarks of egnite, Inc. All other trademarks are the property of their respective owners.

Media Contact

Torrey Loper

480-467-8685

torrey.loper@egnitehealth.com

Linkedin Twitter Youtube

Related Articles
egnite Research

From Black Box to Breakthrough: Unlocking Hidden Care Patterns with LLM-Enriched Data

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
egnite Research

SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.

Figure 1: Observed Mortality Stratified by GLP-1 RA and/or SGLT2i Prescription
egnite Research

Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis

BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized,

© 2025 egnite, Inc. All Rights Reserved. egnite, egnite Inc., CardioCare, the heart logo, and the spark logo are trademarks of egnite, Inc. All other trademarks are property of their respective owners.

Privacy Policy    Intellectual Property    Terms of Use    Implementation Kit    Careers

Linkedin Youtube
Linkedin Twitter

© 2021 egnite, Inc. All Rights Reserved.  egnite, egnite Inc., and the stylized logo are trademarks of egnite, Inc. All other trademarks are property of their respective owners.

CONTACT US